. 2016 Sep 14;22(34):7676–7691. doi: 10.3748/wjg.v22.i34.7676

Table 2.

Impact of immunosuppression withdrawal on preexisting complications in liver transplantation

Author (year)	Ref.	No. of patients	Rational for IS withdrawal	Description of impact on preexisting complications	Impact on preexisting complications in tolerant patients
Mazariegos	[144]	95	Chronic IS-related toxicity	Yes	No changes in renal function or hypertension. Higher survey scores of patients well being
(1997)	[144]	95	Chronic IS-related toxicity	Yes
Devlin	[2]	18	Chronic IS-related toxicity	No	-
(1998)	[2]	18	Chronic IS-related toxicity	No	-
Takatsuki	[161]	63	30 PTLD	No	-
(2001)	[161]	63	30 PTLD	No	-
Eason	[162]	18	Patients who expressed a desire to discontinue IS	No	-
(2005)	[162]	18	Patients who expressed a desire to discontinue IS	No	-
Tryphonopoulos	[163]	104	Role of DBMI in IS withdrawal in LT	No	-
(2005)	[163]	104	Role of DBMI in IS withdrawal in LT	No	-
Orlando	[146]	34	Impact of IS withdrawal on HCV disease in LT	Yes	Less cardiovascular or infectious diseases
(2008)	[146]	34	Impact of IS withdrawal on HCV disease in LT	Yes	Less cardiovascular or infectious diseases
Pons	[148]	22	Chronic IS-related toxicity	Yes	Renal function, hypertension, hypercholesterolemia, hyperuricemia, hypertension and diabetes control improved
(2009)	[148]	22	Chronic IS-related toxicity	Yes
Feng	[147]	20	Chronic IS-related toxicity	Yes	No changes in comorbidities
(2012)	[147]	20	Chronic IS-related toxicity	Yes	No changes in comorbidities
de la Garza	[158]	22	Chronic IS-related toxicity	No	-
(2013)	[158]	22	Chronic IS-related toxicity	No	-
Benitez	[145]	102	Chronic IS-related toxicity	Yes	No changes in comorbidities
(2013)	[145]	102	Chronic IS-related toxicity	Yes	No changes in comorbidities

IS: Immunosuppression; PTLD: Post-transplant lymphoproliferative disorder; HCV: Hepatitis C virus; LT: Liver transplantation; DBMI: Donor bone marrow infusion.